Hiroshi Itoh Selected Research

Heart Failure

12/2022	High body mass index is a risk factor for transition to hemodialysis or hybrid therapy and peritoneal dialysis-related infection in Japanese patients undergoing peritoneal dialysis.
12/2022	Effect of Tolvaptan in Patients with Chronic Kidney Disease Stage G5, and Impact of Concomitant Use of Thiazide Diuretics: A Retrospective Cohort Study.
1/2022	Serial measurement of B-type natriuretic peptide and future cardiovascular events in patients with type 2 diabetes mellitus without known cardiovascular disease.
1/2022	Eosinophilic Reaction at the Time of Catheter Insertion Predicts Survival in Patients Initiating Peritoneal Dialysis.
12/2013	Increased ubiquitination and the crosstalk of G protein signaling in cardiac myocytes: involvement of Ric-8B in Gs suppression by Gq signal.
5/2012	Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.
7/2010	The (pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroshi Itoh Research Topics

Disease

66	Hypertension (High Blood Pressure) 07/2023 - 05/2002
49	Neoplasms (Cancer) 01/2023 - 02/2002
45	Type 2 Diabetes Mellitus (MODY) 01/2023 - 08/2003
33	Insulin Resistance 09/2023 - 07/2003
31	Inflammation (Inflammations) 03/2022 - 12/2006
30	Obesity 03/2024 - 07/2003
23	Chronic Renal Insufficiency 03/2024 - 01/2009
19	Proteinuria 02/2024 - 06/2007
17	Diabetic Nephropathies (Diabetic Nephropathy) 01/2023 - 01/2007
17	Cardiovascular Diseases (Cardiovascular Disease) 01/2023 - 10/2003
17	Hyperaldosteronism (Conn Syndrome) 01/2022 - 03/2002
16	Body Weight (Weight, Body) 07/2023 - 10/2002
15	Infections 01/2023 - 06/2004
15	Albuminuria 10/2019 - 12/2009
14	Chronic Kidney Failure (Chronic Renal Failure) 10/2022 - 01/2007
13	Fibrosis (Cirrhosis) 11/2023 - 07/2007
13	Diabetic Retinopathy (Retinopathy, Diabetic) 05/2022 - 07/2009
13	Atherosclerosis 01/2014 - 01/2002
12	Hypoglycemia (Reactive Hypoglycemia) 05/2023 - 01/2011
12	Diabetes Mellitus 03/2023 - 07/2003
12	Ischemia 11/2019 - 01/2002
12	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2014 - 10/2003
11	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 08/2023 - 11/2007
11	Hyperglycemia 01/2022 - 02/2007
11	Glucose Intolerance 12/2021 - 12/2009
10	Kidney Diseases (Kidney Disease) 01/2023 - 10/2007
10	Hypertrophy 10/2022 - 01/2009
10	Essential Hypertension 01/2022 - 06/2008
9	Renal Insufficiency (Renal Failure) 02/2024 - 11/2008
9	Adenoma (Adenomas) 11/2021 - 03/2002
8	Weight Gain 09/2023 - 01/2008
8	Peritonitis 12/2022 - 01/2015
8	Hypercholesterolemia 05/2022 - 01/2013
8	Stroke (Strokes) 01/2020 - 05/2002
8	Neoplasm Metastasis (Metastasis) 11/2016 - 07/2002
7	Heart Failure 12/2022 - 07/2010
7	Hypoxia (Hypoxemia) 01/2019 - 07/2003
6	Gestational Diabetes (Gestational Diabetes Mellitus) 11/2023 - 06/2010
6	COVID-19 08/2023 - 10/2020
6	Pancreatic Neoplasms (Pancreatic Cancer) 12/2022 - 09/2012
6	Mitochondrial Diseases (Mitochondrial Disease) 09/2022 - 03/2008
6	Weight Loss (Weight Reduction) 01/2021 - 10/2009
6	Hypokalemia 01/2019 - 03/2002
5	Stomach Neoplasms (Stomach Cancer) 02/2024 - 07/2003

Drug/Important Bio-Agent (IBA)

37	Glucose (Dextrose)FDA LinkGeneric 01/2024 - 01/2008
29	Proteins (Proteins, Gene)FDA Link 03/2024 - 04/2002
28	ReninIBA 01/2022 - 03/2002
27	AldosteroneIBA 01/2023 - 03/2002
24	Insulin (Novolin)FDA Link 01/2024 - 01/2008
20	Prorenin ReceptorIBA 06/2018 - 06/2007
17	Biomarkers (Surrogate Marker)IBA 01/2023 - 02/2008
17	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2023 - 05/2002
17	LipidsIBA 05/2022 - 05/2002
16	Angiotensin Receptor AntagonistsIBA 10/2020 - 03/2002
15	Antihypertensive Agents (Antihypertensives)IBA 07/2023 - 05/2002
14	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 03/2023 - 08/2008
14	Messenger RNA (mRNA)IBA 01/2023 - 09/2002
13	SaltsIBA 01/2023 - 05/2002
12	DNA (Deoxyribonucleic Acid)IBA 02/2024 - 12/2002
12	AdiponectinIBA 01/2021 - 07/2003
12	Angiotensin IIIBA 10/2015 - 10/2003
11	CytokinesIBA 09/2017 - 04/2003
10	VaccinesIBA 01/2023 - 09/2011
10	AlbuminsIBA 01/2021 - 01/2011
10	EnzymesIBA 01/2019 - 01/2002
10	Peptides (Polypeptides)IBA 01/2018 - 12/2005
10	AngiotensinsIBA 10/2015 - 01/2009
9	CholesterolIBA 01/2023 - 01/2007
8	Hemoglobins (Hemoglobin)IBA 08/2023 - 01/2011
8	Hormones (Hormone)IBA 12/2021 - 03/2003
8	oxidized low density lipoproteinIBA 12/2021 - 11/2002
8	Streptozocin (Streptozotocin)FDA Link 01/2021 - 01/2008
8	C-Reactive ProteinIBA 01/2021 - 11/2007
8	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2020 - 05/2002
7	LDL CholesterolIBA 05/2022 - 03/2014
7	esaxerenoneIBA 01/2022 - 01/2019
7	AntibodiesIBA 01/2022 - 09/2004
7	AntigensIBA 01/2021 - 10/2007
7	Adrenocorticotropic Hormone (ACTH)FDA Link 03/2020 - 03/2002
6	CreatinineIBA 03/2024 - 02/2009
6	NAD (NADH)IBA 01/2024 - 11/2002
6	SodiumIBA 01/2023 - 05/2010
6	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2002
6	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 04/2013
6	Bile Acids and Salts (Bile Acids)IBA 11/2021 - 07/2011
6	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2020 - 02/2009
6	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 11/2013
6	AdipokinesIBA 01/2019 - 07/2003
6	HGF activatorIBA 09/2018 - 06/2003
6	Transcription Factors (Transcription Factor)IBA 05/2018 - 04/2003
6	MicroRNAs (MicroRNA)IBA 06/2016 - 06/2010
5	HDL CholesterolIBA 11/2023 - 01/2012

Therapy/Procedure

80	Therapeutics 07/2023 - 04/2002
16	Renal Dialysis (Hemodialysis) 12/2022 - 01/2007
13	Peritoneal Dialysis 12/2022 - 09/2011
10	Glycemic Control 11/2023 - 01/2012
8	Drug Therapy (Chemotherapy) 04/2022 - 02/2005
8	Adrenalectomy 11/2021 - 01/2016
7	Catheters 12/2022 - 07/2005
6	Radiotherapy 04/2022 - 07/2002